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ABSTRACT
Purpose: The hypothesis of this study is that EPI-001 that targets the AR NTD will inhibit AR-driven recurrence of prostate cancer resistant to current methods of androgen deprivation or blockade. Scope: Aim 1 will determine the impact of EPI-001 on castration sensitive tumor regression and re-growth in LuCap xenografts and on growth of their castration resistant forms. Aim 2 will examine the impact of EPI-001 on castration sensitive and castration resistant growth of tumors with differing tumor androgen levels and differing ratios of ARv567es to full-length AR. Aim 3 will elucidate the specific molecular mechanisms by which EPI-001 inhibits the activity of full-length AR and truncated ARv567es variants using in vitro models. Progress: Tasks 1 and 3:We have completed the EPI-001 treatment in 5 xenograft lines in the first year of this study. These were done following castration and in castrate resistant growth states. Tasks 4 and 5: We have begun to measure intratumoral androgens and begin IHC analysis of these tumors. A distinct AR variant transcriptome has been identified and reported. Findings: We have clearly shown that EPI-001 can suppress the growth of AR-variant driven prostate cancers. We have also shown that tumors with both AR-full length and variant receptors may respond to both N-and C-terminal agents. Significance: EPI-001 is effective at inhibiting castration resistant prostate cancer driven by AR-variants in vivo. This class of componds should be considered for clinical trial. Appendices…………………………………………………………………………… N/A Introduction: We and others have shown that the emergence of resistance to current methods of androgen receptor blockade including MDV-3100 (enzalutamide) and abiraterone is associated with an increase in androgen receptor (AR) splice variants that are constitutively active andcannot respond to these agents. The purpose of this proposal was to determine if an agent that acts on the Nterminus of the AR which would include the splice variants can suppress the growth of these resistant tumors. Currently, the only Nterminal agent that has been reported is EPI-001. In this study we will evaluate the effects of EPI-001 on a series of human prostate cancer xenografts with variable levels of intracrine androgens and AR splice variants. Work accomplished in year one on Tasks 1, 3,4, and 5
SUBJECT TERMS
We have completed the studies on LuCaP 86.2 and 136 xenografts. LuCap 35v, 96ai, and 23.1 xenografts have also been completed and growth curves and molecular analysis are in process. The results of these studies are presented in graphic form in figure 1. As can be seen EPI-001 performed significantly better than castration alone or MDV3100 in this LuCap 86.2, a variant driven xenograft, p< 0.05 EPI vs castration or MDV3100. Intratumoral steroid levels remained low in this xenograft even with EPI -001 treatment. Since the original publication of this xenograft it has been shown that there is an intragenic rearrangement of the AR gene with a decrease in exons 5, 6, and 7 and potentially the xenograft generates AR v567es via a genomic mechanism rather than non-genomic. The results of LuCaP 136 are interesting as shown in figure 1 in that the xenograft responded to both EPI-001 and MDV3100, p < 0.05 EPI and MDV3100 vs castration. At first glance this appeared to be a dichotomous response but as we have shown (1). LuCaP 136 can express both AR-FL and AR v567es depending on the intracrine androgen status of the tumor. Furthermore, we have shown that LuCaP 136 can alter its androgen profile following castration to either produce testosterone (T) as its intracrine androgen or dihydrotestosterone (DHT). When DHT is produced the tumor responds to MDV3100 but when DHT is shut down we see that it responds to EPI-001. We are currently examining the gene expression responses to therapy in this line.
In figure 2 , we see that treatment with EPI -001 in LuCaP 86.2 tumors decreases the nuclear expression of AR and as shown in figure 1 decreases tumor growth over a 5 week period. This finding was somewhat unexpected because we had not seen abnormalities in nuclear AR localization in our in vitro studies. However, these findings are similar to other N-terminal AR inhibitors that we have studied.
In figure 3 we demonstrated the staining for canonical AR and neuroendocrine proteins in LuCaP 86.2 xenograft tumors.
Additional data that has been published supported in part by this proposal includes a survey of primary prostate cancer and metastases from UW tissue microarrays (2) . Because at least 25 cterminal AR splice variants have been described but antibodies are available for only one of these, we used C-an N-terminal specific AR antibodies to define the incidence of AR variants in primary and metastatic disease. We used the concept that nuclear Nterminal AR antibody staining in the absence of C-terminal would be indicative of a variant. This was born out in the ratio of N-C A.
B. 
